Related Experiment Video
Updated: Jul 13, 2026

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis
Published on: October 13, 2023
Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment
X Clare Zhou1, Sean C Dowdy, Karl C Podratz
1Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Abstract:
Aberrant DNA methylation is an important molecular alteration commonly detected in various malignancies. Hypermethylation and expression silencing have been frequently found in multiple genes including those for steroid receptors, tumor suppressors, and DNA repair factors. Differential DNA methylation patterns are detected in type I and type II endometrial cancers, suggesting divergent epigenetic backgrounds and unique tumorigenic pathways. In this review, the implications of new findings in the field of epigenetics are discussed for endometrial cancer prevention, diagnosis, and treatment. DNA methylation-based assays may be explored as a useful adjunct diagnostic tool. Epigenetic modification reagents, including DNA methyltransferase and histone deacetylase inhibitors, when used alone or in combination with conventional chemotherapy, may be beneficial for endometrial cancer patients. Recent studies on epigenetic reactivation of the progesterone receptor provide a novel approach for re-sensitization of advanced, PR-negative endometrial cancers to progestational therapy.
Insights
Aberrant DNA methylation is a key molecular change in endometrial cancer. Epigenetic strategies show promise for diagnosis, treatment, and preventing cancer by targeting DNA methylation and gene expression.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Aberrant DNA methylation is a hallmark of many cancers, including endometrial cancer.
- Hypermethylation and gene silencing affect critical genes like those for steroid receptors, tumor suppressors, and DNA repair.
- Distinct DNA methylation patterns in type I and type II endometrial cancers indicate different epigenetic landscapes and tumor development pathways.
Purpose of the Study:
- To review the implications of recent epigenetic findings for endometrial cancer.
- To explore the potential of epigenetics in cancer prevention, diagnosis, and treatment.
Main Methods:
- Review of current literature on epigenetics in endometrial cancer.
- Analysis of DNA methylation patterns and their role in tumorigenesis.
- Evaluation of epigenetic modification reagents and their therapeutic potential.
Main Results:
- DNA methylation patterns differ between type I and type II endometrial cancers.
- DNA methylation-based assays may serve as valuable diagnostic tools.
- Epigenetic therapies, including inhibitors of DNA methyltransferase and histone deacetylase, show therapeutic promise.
Conclusions:
- Epigenetic alterations are crucial in endometrial cancer development.
- Epigenetic approaches offer novel strategies for endometrial cancer prevention, diagnosis, and treatment.
- Reactivating progesterone receptor epigenetically can re-sensitize advanced endometrial cancers to therapy.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Cancer Prevention
Some...